drugset / Trial / NCT03664661
BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma
Phase 1
Unknown
15 enrolled
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd. · collab
SequentialOpen-labelTreatment
Summary
Evaluation of the safety and efficacy of BCMA nanobody CAR-T cells in relapsed/refractory myeloma
Timeline
- Start
- 2018-04-11
- Primary completion
- 2019-04-10
- Completion
- 2020-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA nanobody CAR-T cells | Unknown | 5e+06 cells/kg | Other |
| Subject | BCMA nanobody CAR-T cells | Unknown | 1.5e+07 cells/kg | Other |
| Subject | BCMA nanobody CAR-T cells | Unknown | 4.5e+07 cells/kg | Other |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 800 mg/m2 | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |